3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
83
Neoplasm Metastasis
9
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
3
Metastatic Castration-Resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Castration-resistant Prostate Cancer
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
3
belinostat
2
enzalutamide
1
apalutamide
1
abiraterone
1
Quality of Life
1
Patient Reported Outcome Measures
1
PT-100 dipeptide
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Ipilimumab
1
Immunotherapy
1
Fluorouracil
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
abiraterone
×
Genitourinary
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts